Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules

• Published in: Annals of surgical oncology 2021-12, Vol.28 (13), p.8872-8881
• Main Authors: Schumm, Max A., Nguyen, Dalena T., Kim, Jiyoon, Tseng, Chi-Hong, Chow, Amy Y., Shen, Na, Livhits, Masha J.
• Format: Article
• Language: English
• Subjects: Anxiety; Benign; Biopsy; Biopsy, Fine-Needle; Cytology; Endocrine Tumors; Goiter; Humans; Malignancy; Medicine; Medicine & Public Health; Mental depression; Molecular Diagnostic Techniques; Nodules; Oncology; Patients; Prospective Studies; Quality of Life; Retrospective Studies; Surgery; Surgical Oncology; Surveillance; Thyroid; Thyroid gland; Thyroid Neoplasms - diagnosis; Thyroid Neoplasms - genetics; Thyroid Neoplasms - surgery; Thyroid Nodule - diagnosis; Thyroid Nodule - genetics; Thyroid Nodule - surgery; Thyroidectomy; Ultrasonic imaging; Ultrasound
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-021-10375-6

Background Molecular testing can refine the risk of malignancy in cytologically indeterminate thyroid nodules and can reduce the need for diagnostic thyroidectomy. However, quality of life (QOL) in patients mananged with molecular testing is not well studied. Objective We aimed to assess the QOL of patients undergoing surveillance after a benign molecular test result, or thyroidectomy after a suspicious molecular test result. Methods This prospective longitudinal follow-up of the Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules randomized trial utilized the Thyroid-Related Patient-Reported Outcome, 39-item version (ThyPro-39) to assess the QOL of patients with indeterminate cytology on thyroid fine needle aspiration (FNA) biopsy. All patients underwent molecular testing at the time of initial FNA. A mixed-effect model was used to determine changes in QOL over time. Results Of 252 eligible patients, 174 completed the assessment (69% response rate). Molecular test results included 72% ( n =  124) benign and 28% ( n =  50) suspicious. ThyPro-39 scores of benign molecular test patients were unchanged from baseline (following initial FNA and molecular test results) to 18 months of ultrasound surveillance. Baseline symptoms of goiter, anxiety, and depression were more severe for patients with suspicious compared with benign molecular test results. At a median of 8 months after thyroidectomy, suspicious molecular test patients reported improved symptoms of goiter, anxiety, and depression. Conclusion A benign molecular test provides sustained QOL throughout ultrasound surveillance, without worsening anxiety or depression relating to the risk of malignancy. Definitive surgery results in improvement of QOL in patients with suspicious molecular tests.